Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.46 USD | -1.99% | -13.68% | -24.66% |
04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.66% | 45.31M | |
+26.17% | 44.96B | |
-0.80% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.51% | 26.08B | |
-21.48% | 19.03B | |
+6.16% | 12.75B | |
+27.77% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- Chardan Raises PT on Gain Therapeutics to $5.75 From $4 on Plans to Advance Lead Drug Candidate to Clinical Trials, Reiterates Buy Rating